0001415889-24-016672.txt : 20240613 0001415889-24-016672.hdr.sgml : 20240613 20240613161542 ACCESSION NUMBER: 0001415889-24-016672 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240611 FILED AS OF DATE: 20240613 DATE AS OF CHANGE: 20240613 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Posard Matthew L. CENTRAL INDEX KEY: 0001543792 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32335 FILM NUMBER: 241041417 MAIL ADDRESS: STREET 1: 11099 N. TORREY PINES ROAD STREET 2: SUITE 100 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001159036 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 880488686 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12390 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 794-8889 MAIL ADDRESS: STREET 1: 12390 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: HALOZYME THERAPEUTICS INC DATE OF NAME CHANGE: 20040312 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC DATE OF NAME CHANGE: 20010912 4 1 form4-06132024_080638.xml X0508 4 2024-06-11 0001159036 HALOZYME THERAPEUTICS, INC. HALO 0001543792 Posard Matthew L. C/O HALOZYME THERAPEUTICS, INC. 12390 EL CAMINO REAL SAN DIEGO CA 92130 true false false false 0 Common Stock 2024-06-11 4 S 0 10000 50.011 D 109755 D Common Stock 2024-06-12 4 S 0 10000 50.619 D 99755 D Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.00 to $50.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.50 to $50.935. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. /s/ James Oehler, Attorney-in-Fact 2024-06-13